Application No.: 09/836,073 Docket No.: 220002054822

AMENDMENTS TO THE CLAIMS

1. (currently amended) A compound of the formula

$$A_n^1 A_n^2 A_n^3 A_n^4 A A_n^6 I C A_n^9 Q I A_n^{12} Y A_n^{14} F G A_n^{17} F$$
 (1)

and acylated and/or amidated forms thereof,

wherein each n is independently 0 or 1;

 A^{1} , A^{2} and A^{3} are each independently any amino acid;

A⁴, A¹² and A¹⁷ are independently E, D or Q;

A¹⁴ is an aromatic <u>or neutral polar</u> amino acid;

A⁶ and A⁹ represent independently a basic amino acid or a polar neutral amino acid;

wherein each of said amino acids may be in the L form, racemic form, or D form, with the proviso that

the compound of formula (1) does not comprise ALEAKICHQIEYYFGDF when all amino acids are in the L-form, and

must be in isolated form when all amino acids are in the L-form and formula (1) is of the sequence LDLDTKICEQIEYYFGDF, DDADQRIIKQLEYYFGNI_VSKLEASTIRQEYYFGDA or QERAIIRQVEYYFGDF.

- 2. (original) The compound of claim 1 wherein all amino acids are gene encoded.
- 3. (previously presented) The compound of claim 1 wherein all linkages between the amino acids are amide linkages.
- 4. (previously presented) The compound of claim 1 wherein all of the amino acids are in the D form.
- 5. (previously presented) The compound of claim 1 wherein all of the amino acids are in the L form.

sd-276023 3

Application No.: 09/836,073 Docket No.: 220002054822

6. (original) The compound of claim 1 wherein each of A⁴, A¹² and A¹⁷ is independently aspartic or glutamic.

- 7. (previously presented) The compound of claim 1 wherein A¹⁴ is phenylalanine or tyrosine.
 - 8. (canceled)
- 9. (previously presented) The compound of claim 1 wherein each of A⁶ and A⁹ is independently lysine, histidine, arginine, glutamine, or asparagine.
- 10. (previously presented) The compound of claim 1 which is selected from the group consisting of AALEAQICQQIEYYFGDF (SEQ ID NO:2), AALQAKICHQIQYYFGQF (SEQ ID NO:3), QQQEAKICHQIEYYFGDF (SEQ ID NO:4) and AALEAKICHQIEYQFGDF (SEQ ID NO:12).
- 11. (previously presented) [[The]] A compound of claim 1 which is in isolated or purified form and is selected from the group consisting of LDLDTKICEQIEYYFGDF (SEQ ID NO:15), DDADQRIIKQLEYYFGNI (SEQ ID NO:17), VSKLEASTIRQEYYFGDA (SEQ ID NO:18) and QERAIIRQVEYYFGDF (SEQ ID NO:19).
- 12. (original) A pharmaceutical, veterinary or agricultural/horticultural composition which comprises the compound of claim 1 along with a suitable excipient.

13-19. (canceled)

20. (withdrawn) A method to treat viral infection in a plant or animal subject which method comprises administering to said subject an antivirally effective amount of the compound of claim 1.

sd-276023 4

Application No.: 09/836,073 Docket No.: 220002054822

21. (withdrawn) The method of claim 20 wherein said method further comprises administering at least one additional antiviral agent.

- 22. (withdrawn) The method of claim 21 wherein said administering of the compound and said at least one additional antiviral agent is substantially simultaneous.
- 23. (withdrawn) The method of claim 21 wherein said administering of the compound of claim 1 and said at least one antiviral compound is sequential.
- 24. (withdrawn) The method of claim 21 wherein said additional antiviral compound is I-RNA.

25-35. (canceled)

36. (new) A compound of the formula

$$A_{n}^{1} A_{n}^{2} A_{n}^{3} A^{4} A A^{6} I C A^{9} Q I A^{12} Y A^{14} F G A^{17} F$$
 (1)

and acylated and/or amidated forms thereof,

wherein each n is independently 0 or 1;

A¹, A² and A³ are each independently any amino acid;

A⁴, A¹² and A¹⁷ are independently E or D;

A¹⁴ is an aromatic or neutral polar amino acid;

A⁶ and A⁹ represent independently a basic amino acid or a polar neutral amino acid;

wherein each of said amino acids may be in the L form, racemic form, or D form, with the proviso that

the compound of formula (1) does not comprise ALEAKICHQIEYYFGDF when all amino acids are in the L-form.

sd-276023 5